↓ Skip to main content

Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report

Overview of attention for article published in Journal of Medical Case Reports, April 2016
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
26 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report
Published in
Journal of Medical Case Reports, April 2016
DOI 10.1186/s13256-016-0879-6
Pubmed ID
Authors

Yen-Man Lu, Tsu-Ming Chien, Chih-Hung Lin, Chee-Yin Chai, Chun-Nung Huang

Abstract

Currently, there is no standard salvage regimen after the failure of cisplatin-based chemotherapy for advanced urothelial carcinoma. The combination of epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan was originally designed for the treatment of metastatic colorectal cancer. Until now, there have been no reports using this combination therapy in treating advanced upper tract urothelial carcinoma. To the best of our knowledge, this is the first report showing this possible treatment regimen for advanced upper tract urothelial carcinoma. We report the case of a 90-year-old Chinese woman who was diagnosed with metastatic colorectal cancer and urothelial carcinoma of the bladder, ureter, and renal pelvis. The upper tract urothelial carcinoma was well controlled by the chemotherapy regimen for metastatic colorectal cancer. Considering her age, we used only laser ablation for the treatment of her urothelial carcinoma in combination with intravesical mitomycin C chemotherapy. Follow-up cystoscopy and ureterorenoscopy showed an unexpected regression of the upper tract urothelial tumor. Contrast-enhanced computed tomography also demonstrated the same results. This novel regimen for the treatment of upper tract urothelial carcinoma may merit further investigation or evaluation in clinical trials.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 26 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 23%
Other 5 19%
Student > Master 4 15%
Student > Ph. D. Student 4 15%
Researcher 3 12%
Other 2 8%
Unknown 2 8%
Readers by discipline Count As %
Medicine and Dentistry 9 35%
Chemistry 3 12%
Nursing and Health Professions 2 8%
Biochemistry, Genetics and Molecular Biology 1 4%
Economics, Econometrics and Finance 1 4%
Other 3 12%
Unknown 7 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 April 2016.
All research outputs
#18,453,763
of 22,865,319 outputs
Outputs from Journal of Medical Case Reports
#2,263
of 3,927 outputs
Outputs of similar age
#219,036
of 299,111 outputs
Outputs of similar age from Journal of Medical Case Reports
#34
of 61 outputs
Altmetric has tracked 22,865,319 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,927 research outputs from this source. They receive a mean Attention Score of 3.9. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 299,111 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 61 others from the same source and published within six weeks on either side of this one. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.